Gastrin antagonists in the treatment of gastric cancer

S A Watson1, R J Steele

  • 1Department of Surgery, Queens Medical Centre, University of Nottingham, UK.

Anti-Cancer Drugs
|December 1, 1993
PubMed

Insights

Gastrin fuels human gastric cancer growth via specific receptors. Therapies targeting gastrin's proliferative effects, including receptor antagonists and anti-secretory agents, are under investigation for clinical use.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Gastrin, a polypeptide hormone, significantly promotes human gastric cancer cell proliferation.
  • Gastrin's growth-promoting effects are mediated by high-affinity, membrane-associated receptors on cancer cells.
  • Gastrin may function as an autocrine mediator, stimulating gastric tumor cell proliferation.

Purpose of the Study:

  • To explore therapeutic strategies targeting the gastrin pathway in human gastric cancer.
  • To evaluate agents that antagonize gastrin receptor binding for potential clinical application.
  • To investigate alternative anti-gastrin therapies, including anti-secretory agents and those inducing anti-gastrin antibodies.

Main Methods:

  • Development and evaluation of gastrin receptor antagonists.
  • Investigation of anti-secretory agents to reduce gastrin levels.
  • Exploration of therapeutic agents that stimulate the in situ production of neutralizing anti-gastrin antibodies.

Main Results:

  • Gastrin receptor antagonists have been developed and evaluated for clinical potential.
  • Anti-secretory agents have been investigated as a therapeutic approach.
  • Agents inducing anti-gastrin antibodies in situ are also under study.

Conclusions:

  • Targeting the gastrin pathway presents a promising therapeutic avenue for human gastric cancer.
  • Multiple anti-gastrin strategies, including receptor blockade and modulation of gastrin levels, are being explored.
  • Further research into these therapies may lead to novel treatments for gastric cancer.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...